News headlines about Becton Dickinson and (NYSE:BDX) have been trending somewhat positive on Friday, according to Accern Sentiment. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Becton Dickinson and earned a news impact score of 0.16 on Accern’s scale. Accern also gave media stories about the medical instruments supplier an impact score of 45.5388409217916 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the news articles that may have effected Accern’s rankings:
- Becton Dickinson and (BDX) Stock Rating Reaffirmed by Wells Fargo (americanbankingnews.com)
- Varian’s HyperArc: Driven by Rising Metastatic Brain Cancer? (finance.yahoo.com)
- Global Breathing Exercise Devices Market 2018 – Becton, Dickinson, Cardinal Health, Smiths Medical, Nidek Medical … (journalhealthcare.com)
- Is Stock’s Performance Impressive? – Becton Dickinson and Company (NYSE: BDX) (alphabetastock.com)
- See what the IHS Markit Score report has to say about Becton Dickinson and Co. (finance.yahoo.com)
A number of research analysts have issued reports on BDX shares. Argus lifted their target price on Becton Dickinson and to $235.00 and gave the company a “buy” rating in a research report on Thursday, December 14th. They noted that the move was a valuation call. Deutsche Bank set a $260.00 target price on Becton Dickinson and and gave the company a “buy” rating in a research report on Friday, December 29th. Evercore ISI began coverage on Becton Dickinson and in a research report on Wednesday, January 3rd. They issued an “outperform” rating and a $245.00 target price on the stock. Zacks Investment Research upgraded Becton Dickinson and from a “hold” rating to a “buy” rating and set a $240.00 price target on the stock in a report on Wednesday, January 3rd. Finally, KeyCorp began coverage on Becton Dickinson and in a report on Friday, January 5th. They set an “overweight” rating and a $260.00 price target on the stock. Six analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $240.53.
Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings data on Tuesday, February 6th. The medical instruments supplier reported $2.48 EPS for the quarter, topping the Zacks’ consensus estimate of $2.41 by $0.07. The company had revenue of $3.08 billion for the quarter, compared to analyst estimates of $3.05 billion. Becton Dickinson and had a return on equity of 16.19% and a net margin of 2.71%. The firm’s quarterly revenue was up 5.4% on a year-over-year basis. During the same period in the previous year, the firm earned $2.33 earnings per share. equities analysts predict that Becton Dickinson and will post 10.95 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Friday, March 30th. Investors of record on Friday, March 9th were paid a $0.75 dividend. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.36%. The ex-dividend date of this dividend was Thursday, March 8th. Becton Dickinson and’s dividend payout ratio is currently 31.65%.
In related news, EVP Thomas E. Polen, Jr. sold 1,877 shares of Becton Dickinson and stock in a transaction that occurred on Tuesday, March 13th. The stock was sold at an average price of $227.00, for a total value of $426,079.00. Following the transaction, the executive vice president now directly owns 15,387 shares of the company’s stock, valued at $3,492,849. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP John E. Gallagher sold 5,346 shares of Becton Dickinson and stock in a transaction that occurred on Tuesday, February 27th. The stock was sold at an average price of $226.08, for a total value of $1,208,623.68. Following the completion of the transaction, the vice president now directly owns 9,391 shares in the company, valued at $2,123,117.28. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 281,108 shares of company stock worth $61,321,396. 1.00% of the stock is owned by insiders.
COPYRIGHT VIOLATION WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect Becton Dickinson and (NYSE:BDX) Stock Price” was reported by BBNS and is the property of of BBNS. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at https://baseballnewssource.com/2018/04/06/becton-dickinson-and-bdx-receives-daily-news-impact-score-of-0-16/2030681.html.
Becton Dickinson and Company Profile
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.